U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher, except for the small-cap gauge Russell 2000.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.
Bristol-Myers Squibb (BMY) offers a high 5.06% dividend yield, strong profitability, and solid financial health, making it a top pick for income investors. Its undervalued stock and consistent payout growth add to its appeal.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.
